InflaRx (IFRX) FCF Margin (2018 - 2026)

InflaRx (IFRX) posted FCF Margin of 461.3% for Q1 2026, up 4605.24% sequentially from 10.24% in Q4 2025, and up 3932477.0% YoY from N/an in Q1 2025.

InflaRx (IFRX) FCF Margin (2018 - 2026) Analysis & Trends

InflaRx has reported FCF Margin for 9 years, with the latest figure at 461.3% in Q1 2026.

Quarterly FCF Margin rose 3932477.0% year-over-year to 461.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61.48% (up 2887.0% YoY) and the FY2025 annual result came in at 73.42%, up 1827.0% from the prior year.
FCF Margin rose to 461.3% in Q1 2026 per IFRX's latest filing, from 10.24% in the prior quarter.
Over five years, FCF Margin peaked at 1544.14% in Q1 2022 and troughed at 190687.89% in Q2 2024.
A 5-year average of 19633.11% and a median of 24.53% in 2023 frame the typical range for FCF Margin.
The sharpest annual moves came in 2024 and 2025: FCF Margin plunged 19135893 bps in 2024, then soared 17157177 bps in 2025.
Over 5 years, FCF Margin stood at 1524.72% in 2022, then jumped by 98 bps to 24.53% in 2023, then advanced by 8 bps to 22.66% in 2024, then soared by 55 bps to 10.24% in 2025, then surged by 4605 bps to 461.3% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 461.3%, 10.24%, and 37566.05% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.69 Bn	131.84 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.46 Bn	78.47 Bn	3.93 Bn	13.35%
3	Argenx Se	65.62 Bn	60.44 Bn	1.37 Bn	-
4	Moderna	58.37 Bn	53.24 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.73 Bn	28.43 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.27 Bn	9.87 Bn	668.28 Mn	41.07%
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.23 Bn	26.40 Bn	-	70.82%
10	InflaRx	140.63 Mn	-43.63 Mn	2.74 Bn	-6,436.31%

Download Data